Volume 88, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Cutaneous leishmaniasis is clinically widespread but lacks treatments that are effective and well tolerated. Because all present drugs have been grandfathered into clinical use, there are no examples of a pre-clinical product evaluation scheme that lead to new candidates for formal development. To provide oral agents for development targeting cutaneous leishmaniasis, we have implemented a discovery scheme that incorporates and testing of efficacy, toxicity, and pharmacokinetics/metabolism. Particular emphasis is placed on testing, progression from higher-throughput models to those with most clinical relevance, and efficient use of resources.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Desjeux P, , 2001. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 95: 239243.[Crossref] [Google Scholar]
  2. World Health Organization, 2010. Control of the leishmaniases. World Health Organ Tech Rep Ser 949: 1186. [Google Scholar]
  3. Gonzalez U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, Alvar J, , 2010. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 51: 409419.[Crossref] [Google Scholar]
  4. Sharlow ER, Grögl M, Johnson J, Lazo JS, , 2010. Anti-leishmanial drug discovery: rising to the challenges of a highly neglected disease. Mol Interv 10: 7275.[Crossref] [Google Scholar]
  5. Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, Haj Hamida NB, El Ahmadi Z, Downs MT, Smith PL, Dellagi K, Grögl M, , 2009. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a Phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 3: e432.[Crossref] [Google Scholar]
  6. Sharlow ER, Close D, Shun T, Leimgruber S, Reed R, Mustata G, Wipf P, Johnson J, O'Neil M, Grögl M, Magill AJ, Lazo JS, , 2009. Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis 3: e540.[Crossref] [Google Scholar]
  7. Sharlow ER, Leimgruber S, Yellow-Duke A, Barrett R, Wang QJ, Lazo JS, , 2008. Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries. Nat Protoc 3: 13501363.[Crossref] [Google Scholar]
  8. De Muylder G, Ang KK, Chen S, Arkin MR, Engel JC, McKerrow JH, , 2011. A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis 5: e1253.[Crossref] [Google Scholar]
  9. Zhu X, Pandharkar T, Werbovetz K, , 2012. Identification of new antileishmanial leads from hits obtained by high-throughput screening. Antimicrob Agents Chemother 56: 11821189.[Crossref] [Google Scholar]
  10. Sakthianandeswaren A, Foote SJ, Handman E, , 2009. The role of host genetics in leishmaniasis. Trends Parasitol 25: 383391.[Crossref] [Google Scholar]
  11. Hanson WL, Chapman WL, Waits VL, Lovelace JK, , 1991. Development of Leishmania (Vianna) panamensis lesions and relationship of numbers of amastigotes to lesion areas on antimony-treated and untreated hamsters. J Parasitol 77: 780783.[Crossref] [Google Scholar]
  12. Mortelmans K, Zeiger E, , 2000. The Ames Salmonella/M microsome mutagenicity assay. Mutat Res 455: 2960.[Crossref] [Google Scholar]
  13. Fenech M, , 2000. The in vitro micronucleus technique. Mutat Res 455: 8195.[Crossref] [Google Scholar]
  14. Sanguinetti M, Mitcheson J, , 2005. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26: 119124.[Crossref] [Google Scholar]
  15. Serrano-Martín X, Payares G, De Lucca M, Martinez JC, Mendoza-León A, Benaim G, , 2009. Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 53: 51085113.[Crossref] [Google Scholar]
  16. Silva-Almeida M, Carvalho LO, Abreu-Silva AL, d'Escoffier LN, Calabrese KS, , 2010. Leishmania (Leishmania) amazonensis infection: muscular involvement in BALB/c and C3H.HeN mice. Exp Parasitol 124: 315318.[Crossref] [Google Scholar]
  17. Castilho TM, Goldsmith-Pestana K, Lozano C, Valderrama L, Saravia NG, McMahon-Pratt D, , 2010. Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease. Eur J Immunol 40: 28162829.[Crossref] [Google Scholar]
  18. Tonui W, Titus RG, , 2007. Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB/C mice. Am J Trop Med Hyg 76: 579584. [Google Scholar]
  19. Morais-Teixeira E, Carvalho AS, Costa J, Duarte SL, Mendonça JS, Boechat N, Rabello A, , 2008. In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L. (L.) chagasi and L. (Viannia) braziliensis . Mem Inst Oswaldo Cruz 103: 358362.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 30 Dec 2011
  • Accepted : 03 Nov 2012
  • Published online : 06 Feb 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error